Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$5.23 USD
+0.16 (3.15%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.49 +0.26 (4.97%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
WINT 5.23 +0.16(3.15%)
Will WINT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for WINT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WINT
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
WINT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for WINT
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers
Windtree Therapeutics Inc trading halted, news pending
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Windtree Therapeutics Announces Reverse Stock Split